Table 2.

Distribution of biomarkers contributing to AL scores among Black breast cancer survivors in the Women's Circle of Health Follow-Up Study (2014–2018), by AL measure cohort.

AL measure 1a cohort (n = 229)AL measure 2b cohort (n = 409)
BiomarkersMean ± SDMean ± SD
 AL score3.09 ± 1.463.15 ± 1.61
 SBP (mm Hg)133.47 ± 16.53130.74 ± 17.14
 DBP (mm Hg)79.70 ± 9.5478.57 ± 10.18
 HDL (mg/dL)61.42 ± 17.85
 LDL (mg/dL)124.12 ± 106.55
 Total cholesterol (mg/dL)193.56 ± 38.00
 Triglycerides (mg/dL)102.87 ± 52.40
 Waist circumference (cm)103.87 ± 16.62102.45 ± 15.74
 Glucose level (mg/dL)111.43 ± 54.70107.39 ± 47.90
 Albumin level (g/dL)4.41 ± 3.92
Biomarkersn (%)n (%)
 ALc
  Low (0–3 points)149 (65.1)227 (55.5)
  High (4–8 points)80 (34.9)182 (44.5)
 SBP ≥140 mm Hg
  Yes79 (34.5)120 (29.3)
  No150 (65.5)289 (70.7)
 DBP ≥90 mm Hg
  Yes40 (17.5)64 (15.6)
  No189 (82.5)345 (84.4)
 HDL <50 mg/dL
  Yes66 (28.8)
  No163 (71.2)
 LDL ≥130 mg/dL
  Yes66 (28.8)
  No163 (71.2)
 Total cholesterol ≥240 mg/dL
  Yes29 (12.7)
  No200 (87.3)
 Abnormal total cholesterol or LDL leveld
  Yes67 (29.3)
  No162 (70.7)
 Triglycerides ≥150 mg/dL
  Yes29 (12.7)
  No200 (87.3)
 Glucose level ≥110 mg/dL
  Yes55 (24.0)106 (25.9)
  No174 (76.0)303 (74.1)
 Waist circumference ≥88 cm
  Yes194 (84.7)338 (82.6)
  No35 (15.3)71 (17.4)
 History of use of medications to control diabetes, hypertension, or hypercholesterolemia
  Yes177 (77.3)285 (69.7)
  No52 (22.7)124 (30.3)
 Albumin <4.0 g/dL
  Yes111 (27.1)
  No298 (72.9)
 eGFR <59 mL/min
  Yes38 (9.3)
  No371 (90.7)
 BMI ≥30 kg/m2
  Yes228 (55.8)
  No181 (44.2)
  • Note: Percentages may not sum to 100 due to rounding.

  • aAL measure 1 was computed on the basis of the following biomarkers: SBP, DBP, waist circumference, glucose level, HDL, triglycerides, total cholesterol and/or LDL, and use of medication to control hypertension, hypercholesterolemia, or diabetes.

  • bAL measure 2 was computed on the basis of the following biomarkers: SBP, DBP, waist circumference, glucose level, albumin, eGFR, BMI, and use of medication to control hypertension, hypercholesterolemia, or diabetes.

  • cThe median AL score (for both measures) among Women's Circle of Health Follow-Up Study participants was 3. Thus, 3 was used as the cutoff point to dichotomize the AL variables.

  • dAbnormal total cholesterol or LDL level was defined as (i) total cholesterol >240 mg/dL or (ii) total cholesterol ≤240 mg/dL and LDL >130 mg/dL.